Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 851.49B | 858.25B | 798.68B | 679.74B | 679.50B |
Gross Profit | 190.18B | 184.13B | 160.62B | 148.08B | 189.09B |
EBITDA | 82.05B | 76.91B | 59.55B | 58.35B | 54.91B |
Net Income | 34.69B | 31.74B | -10.38B | 17.51B | 19.01B |
Balance Sheet | |||||
Total Assets | 789.71B | 826.70B | 713.87B | 723.07B | 687.41B |
Cash, Cash Equivalents and Short-Term Investments | 96.12B | 109.47B | 82.97B | 70.71B | 61.73B |
Total Debt | 84.53B | 88.31B | 85.05B | 79.51B | 76.95B |
Total Liabilities | 287.14B | 310.32B | 275.38B | 262.43B | 242.64B |
Stockholders Equity | 485.01B | 500.30B | 423.88B | 449.27B | 433.20B |
Cash Flow | |||||
Free Cash Flow | 13.74B | 44.00B | 4.76B | 23.15B | 32.15B |
Operating Cash Flow | 55.21B | 73.19B | 23.42B | 41.83B | 49.51B |
Investing Cash Flow | -34.96B | -30.94B | 487.00M | -15.52B | -17.11B |
Financing Cash Flow | -35.43B | -19.54B | -10.63B | -17.85B | -31.26B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Neutral | ¥484.84B | 14.57 | 3.51% | -0.79% | 9.61% | ||
65 Neutral | $26.77B | 15.22 | -4.18% | 3.21% | 1.01% | 1.53% | |
― | $2.31B | 16.15 | 10.34% | 2.27% | ― | ― | |
― | $5.84B | 16.73 | 11.20% | 2.31% | ― | ― | |
― | $1.13B | 7.25 | 10.43% | 3.12% | ― | ― | |
― | $4.26B | 17.25 | 8.78% | 1.22% | ― | ― | |
― | €918.85M | 11.07 | 6.86% | 3.67% | ― | ― |
Nisshin Seifun Group Inc. has announced a plan to continue its strategy of issuing subscription rights to shares as a measure to enhance corporate value and protect shareholder interests. The company has filed a shelf registration for these rights, allowing for a prompt response if the plan is implemented, with a scheduled issuance amount of ¥642,198,000.
The most recent analyst rating on (JP:2002) stock is a Hold with a Yen2000.00 price target. To see the full list of analyst forecasts on Nisshin Seifun Group Inc. stock, see the JP:2002 Stock Forecast page.
Nisshin Seifun Group Inc. announced the continuation of its takeover response policies, initially introduced in 2006, to protect and enhance corporate value and shareholder interests. The plan involves the use of subscription rights to shares as a countermeasure against potential hostile takeovers, ensuring the company remains in control of its strategic direction and maintains stability for its stakeholders.
The most recent analyst rating on (JP:2002) stock is a Hold with a Yen2000.00 price target. To see the full list of analyst forecasts on Nisshin Seifun Group Inc. stock, see the JP:2002 Stock Forecast page.
Nisshin Seifun Group Inc. is restructuring its business portfolio to align with its Medium-Term Management Plan 2026, aiming for sustainable growth. As part of this restructuring, Nisshin Pharma will cease its fine chemicals business and transfer its healthcare foods business to Oriental Yeast Co., Ltd., which is expected to enhance the healthcare foods segment. This move is driven by a challenging business environment for Nisshin Pharma’s fine chemicals and aims to leverage Oriental Yeast’s capabilities in food materials. The restructuring will result in an extraordinary loss of 2,276 million yen, impacting the company’s financial results.
Nisshin Seifun Group Inc. reported a slight decrease in net sales and operating profit for the fiscal year ending March 31, 2025, compared to the previous year. Despite this, the company increased its dividends per share, indicating a commitment to shareholder returns. The forecast for the next fiscal year shows a modest growth in net sales and profits, suggesting a positive outlook for the company’s financial performance.
Nisshin Seifun Group Inc. announced a change in its executive leadership, with Kenji Sakamoto appointed as the new Representative Director and Senior Managing Executive Officer, replacing Naoto Masujima, who will become a Senior Corporate Adviser. This leadership transition is part of the company’s strategic restructuring to enhance its executive framework, potentially impacting its operational efficiency and industry positioning.